Conversely, the astrocytic marker, GFAP, demonstrated a significant elevation in accordance with AD diagnosis (Fig. 3b(i, ii), p < 0.01), and AD pathological severity (Fig. 3b(iii), p < 0.01). This evidence concerns the gene GFAP and Alzheimer disease.